Viridian Therapeutics, Inc.
VRDN Healthcare Biotechnology
Viridian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.8 million, up 23,359.9% from fiscal 2024. In the quarter to June 2026, revenue grew 278.7%, EPS fell 5.00%, free cash flow fell 41.4% and total debt rose 1,064.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow VRDN
Viridian Therapeutics, Inc. (VRDN) EV/Sales
As of 16 October 2026, Viridian Therapeutics, Inc. (VRDN) trades at a EV/Sales of 18.6×. Over the past ten years it has ranged from −37.3× (March 2021) to 4,002× (September 2025); the current reading is higher than 56% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 25.7× | (98.72%) |
| FY2024 | 2,004× | 15.68% |
| FY2023 | 1,732× | 519.88% |
| FY2022 | 279× | 1,984.96% |
| FY2021 | 13.4× | — |
| FY2020 | −35.6× | — |
| FY2019 | −0.8× | — |
| FY2018 | 4.4× | (89.10%) |
| FY2017 | 40.7× | — |
| FY2016 | −4.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 17.6× | (3.76%) |
| Mar 2026 | 18.3× | (28.97%) |
| Dec 2025 | 25.7× | 39.74% |
| Sep 2025 | 18.4× | (99.06%) |
| 41 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IRON Disc Medicine, Inc. compare | n/m |
| FTRE Fortrea Holdings Inc. compare | 1.1× |
| HRMY Harmony Biosciences Holdings, Inc. compare | 1.8× |
| NVAX Novavax, Inc. compare | 3.4× |
| AUPH Aurinia Pharmaceuticals Inc compare | 5.6× |
| VRDN Viridian Therapeutics, Inc. | 18.6× |
| RXRX Recursion Pharmaceuticals, Inc. compare | 23.7× |
| SLS SELLAS Life Sciences Group, Inc. compare | 167× |
| CLDX Celldex Therapeutics, Inc. compare | 1,610× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)